Chavanet P Y, Bailly F, Mousson C, Waldner-Combernoux A, Lokiec F, Rebibou J M, Chalopin J M, Portier H
Service des Maladies Infectieuses et Tropicales, Hopital du Bocage, Dijon, France.
J Clin Apher. 1990;5(2):68-9.
During experimental treatment of human immunodeficiency virus (HIV-1) infection using high doses of acyclovir (ACV) (600 mg IV every 8 h), cyclosporin, and several courses of plasmapheresis (PE) (60 ml/kg), ACV pharmacokinetics in three patients have been measured. The results with or without PE were not significantly different: half-time of elimination 3 vs. 2.3 h, volume of distribution 1.8 vs. 1.14 liter/kg, and total clearance 404 vs. 314 ml/min. The clearance and the fraction of elimination due to PE were 5.27 ml/min and 2.5%, respectively. These findings suggest that supplemental doses of ACV are not needed when plasmapheresis is performed.
在使用高剂量阿昔洛韦(ACV)(每8小时静脉注射600毫克)、环孢素以及几个疗程的血浆置换(PE)(60毫升/千克)对人类免疫缺陷病毒(HIV-1)感染进行实验性治疗期间,对三名患者的ACV药代动力学进行了测定。有或无PE时的结果无显著差异:消除半衰期分别为3小时和2.3小时,分布容积分别为1.8升/千克和1.14升/千克,总清除率分别为404毫升/分钟和314毫升/分钟。PE导致的清除率和消除分数分别为5.27毫升/分钟和2.5%。这些发现表明,进行血浆置换时无需补充ACV剂量。